Please Wait.....
Report
Short Bowel Syndrome - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 110 Pages I Mordor Intelligence
Short Bowel Syndrome Market Analysis
The Short Bowel Syndrome market is valued at USD 1.53 billion in 2025 and is forecast to reach USD 2.22 billion by 2030, advancing at a 7.75% CAGR. Current expansion is propelled by earlier disease recognition, faster orphan-drug approvals, and tissue-engineering breakthroughs that promise anatomical restoration rather than symptomatic relief. New ICD-10 codes introduced by the Centers for Medicare & Medicaid Services (CMS) in October 2023 are uncovering previously unreported cases and widening the treated population. At the same time, digital health platforms are making home parenteral nutrition (PN) feasible for a larger share of patients, lowering inpatient costs and improving adherence. Competitive intensity is moderate because GLP-2 analogs dominate therapy choices, yet manufacturing bottlenecks, long-term safety monitoring, and rising reimbursement scrutiny create palpable risks. Still, regulatory incentives for rare diseases and converging tissue-engineering research are reshaping the Short Bowel Syndrome market outlook over the next five years.
Global Short Bowel Syndrome Market Trends and Insights
Rising Prevalence of SBS & Complex GI Surgeries
Neonatal surgical advances have lifted survival in very low birth-weight infants, yet they have also pushed neonatal SBS incidence to 22.1 per 1,000 NICU admissions in recent cohorts . Adult incidence is rising for similar reasons: oncologic and inflammatory bowel resections are now more radical, preserving life but shortening bowel length. CMS coding changes in 2023 created visibility for these additional cases, encouraging earlier referrals and stimulating demand for novel therapeutics.
Accelerated Approvals & Uptake of GLP-2 Analogs
The FDA expanded teduglutide to children aged ?1 year and granted fast-track status to newer molecules such as apraglutide and sonefpeglutide, creating a virtuous cycle of innovation and access. Takeda's Gattex/Revestive posted JPY 119.3 billion sales in fiscal 2024, up 28.1% year over year . Conversely, Zealand Pharma's glepaglutide received a Complete Response Letter in December 2024, highlighting the market's regulatory volatility.
High Therapy Cost & Limited Access in LMICs
Total annual therapy costs exceed USD 43,000 per patient when factoring PN, monitoring, and complication management. Many LMIC health systems lack reimbursement frameworks or the cold-chain logistics for GLP-2 analogs. Manufacturers are experimenting with tiered pricing, but infrastructure constraints persist, motivating interest in low-cost peptides or simplified PN regimens.
Other drivers and restraints analyzed in the detailed report include:
Orphan-Drug Incentives & Favorable Reimbursement / Global Patient-Registry & NGO Awareness Initiatives / Tissue-Engineered Intestine R&D Breakthroughs / Serious Long-Term Safety Concerns (e.g., Neoplasia) /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
GLP-2 analogs accounted for 96.14% of the Short Bowel Syndrome market in 2024, propelled by teduglutide's robust evidence base. Growth hormone therapies, though smaller in absolute sales, are set for 8.25% CAGR through 2030 as pediatric specialists employ them to spur mucosal adaptation. Weekly and monthly GLP-2 candidates like apraglutide and sonefpeglutide seek to reduce injection burden, whereas OPKO Health and Entera Bio are developing the first oral GLP-2 peptide, a shift that could reposition the Short Bowel Syndrome market size for maintenance therapy. Competitive differentiation now centers on dosing convenience, safety, and incremental PN-reduction data to secure payer acceptance and justify premium prices.
Future uptake will hinge on real-world evidence showing durable PN reduction and manageable colonoscopic surveillance. If next-generation molecules confirm similar efficacy with fewer polyps, the Short Bowel Syndrome market could migrate quickly, fragmenting the current GLP-2 oligopoly. Conversely, any class-wide safety signal could redirect investment toward regenerative or gene-editing modalities.
The Report Covers Malabsorption Syndrome Market Growth & Trends and the Market is Segmented by Drug Class (GLP-2, Growth Hormone, Glutamine, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), Patient Age Group (Adults and Pediatrics) and Geography. The Market Provides the Value (in USD Million) for the Above-Mentioned Segments.
Geography Analysis
North America generated 42.41% of the Short Bowel Syndrome market in 2024, supported by specialized intestinal-failure centers, Medicare PN reimbursement, and early access to GLP-2 analogs. CMS coding updates and commercial coverage expansions ensure treatment visibility and financial viability, yet payer criteria remain stringent and require documentation of 12-month PN dependence in some plans.
Europe retains critical mass through centralized care networks and harmonized guidelines. NICE's commercial arrangement for teduglutide and ESPEN's multidisciplinary standards provide structure and reduce therapeutic variability. EU clinical consortia also drive first-in-human tissue-engineering trials, strengthening the region's innovation footprint.
Asia-Pacific is the fastest-growing territory at 9.34% CAGR through 2030, driven by regulatory modernization in China and increased resection volumes tied to rising colorectal cancer incidence. China's 2023 regulations on special-medical-purpose formula expand access to nutritionally balanced enteral feeds, complementing PN and pharmacotherapy. Japan's inclusion in global apraglutide trials exemplifies the region's integration into pivotal studies, accelerating time-to-approval for novel agents.
List of Companies Covered in this Report:
Takeda Pharmaceuticals / Zealand Pharma / VectivBio / Ironwood Pharmaceuticals / OxThera AB / Nutrinia Ltd. / Merck / Ardelyx Inc. / Nestle Health Science / Hanmi Pharmaceutical / 9 Meters Biopharma / Opko Health / Jaguar Health / Pfizer / Abbvie / Kyowa Kirin / Johnson&Johnson /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising prevalence of SBS & complex GI surgeries
4.2.2 Accelerated approvals & uptake of GLP-2 analogs
4.2.3 Orphan-drug incentives & favourable reimbursement
4.2.4 Global patient-registry & NGO awareness initiatives
4.2.5 Tissue-engineered intestine R&D breakthroughs
4.2.6 Remote PN-monitoring digital platforms
4.3 Market Restraints
4.3.1 High therapy cost & limited access in LMICs
4.3.2 Serious long-term safety concerns (e.g., neoplasia)
4.3.3 Peptide-manufacturing supply-chain bottlenecks
4.3.4 Disruptive competition from microbiome & surgical innovations
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value)
5.1 By Drug Class
5.1.1 GLP-2 Analogues
5.1.2 Growth Hormone
5.1.3 Glutamine
5.1.4 Others
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online & Others
5.3 By Patient Age Group
5.3.1 Adults (?18 yrs)
5.3.2 Pediatrics (<18 yrs)
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Takeda Pharmaceutical Co. Ltd.
6.3.2 Zealand Pharma
6.3.3 VectivBio AG
6.3.4 Ironwood Pharmaceuticals
6.3.5 OxThera AB
6.3.6 Nutrinia Ltd.
6.3.7 Merck KGaA
6.3.8 Ardelyx Inc.
6.3.9 Nestle Health Science
6.3.10 Hanmi Pharmaceutical
6.3.11 9 Meters Biopharma
6.3.12 OPKO Health Inc.
6.3.13 Jaguar Health
6.3.14 Pfizer Inc.
6.3.15 AbbVie Inc.
6.3.16 Kyowa Kirin
6.3.17 Johnson & Johnson (Janssen)
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security